Pure Bioscience, Inc. (PURE) stock
PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
$0.07−0.01 (-12.10%)
Close on Oct 19, 2026Market cap $8.67MP/E –Yield –
Pure Bioscience ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Pure Bioscience's ebitda for the twelve months ending Jul 31, 2024 was -$3.04M. For fiscal 2026 it was -$2.08M. The highest annual figure on record is $196.00K in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | -$2.08M | – |
| FY2025 | Jul 31, 2025 | -$2.27M | – |
| FY2024 | Jul 31, 2024 | -$3.04M | – |
| FY2023 | Jul 31, 2023 | -$3.83M | – |
| FY2022 | Jul 31, 2022 | -$3.51M | – |
| FY2021 | Jul 31, 2021 | -$2.14M | -1191.3% |
| FY2020 | Jul 31, 2020 | $196.00K | – |
| FY2019 | Jul 31, 2019 | -$5.35M | – |
| FY2018 | Jul 31, 2018 | -$6.76M | – |
| FY2017 | Jul 31, 2017 | -$5.73M | – |
| FY2016 | Jul 31, 2016 | -$6.84M | – |
| FY2015 | Jul 31, 2015 | -$7.43M | – |
| FY2014 | Jul 31, 2014 | -$11.65M | – |
| FY2013 | Jul 31, 2013 | -$7.03M | – |
| FY2012 | Jul 31, 2012 | -$8.37M | – |
| FY2011 | Jul 31, 2011 | -$7.90M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | -$661.00K | – |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | -$781.00K | – |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | -$927.00K | – |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | -$674.00K | – |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | -$1.01M | – |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | -$840.00K | – |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | -$1.02M | – |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | -$956.00K | – |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | -$1.18M | – |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | -$707.00K | – |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | -$888.00K | – |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | -$737.00K | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | -$689.00K | -150.3% |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | -$767.00K | -247.8% |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | -$549.00K | – |
| Q1 FY2021CQ3 2020 | Oct 31, 2020 | -$134.00K | – |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | $1.37M | – |
| Q3 FY2020CQ1 2020 | Apr 30, 2020 | $519.00K | – |
| Q2 FY2020CQ4 2019 | Jan 31, 2020 | -$615.00K | – |
| Q1 FY2020CQ3 2019 | Oct 31, 2019 | -$1.08M | – |
| Q4 FY2019CQ2 2019 | Jul 31, 2019 | -$772.00K | – |
| Q3 FY2019CQ1 2019 | Apr 30, 2019 | -$864.00K | – |
| Q2 FY2019CQ4 2018 | Jan 31, 2019 | -$1.22M | – |
| Q1 FY2019CQ3 2018 | Oct 31, 2018 | -$2.49M | – |
| Q4 FY2018CQ2 2018 | Jul 31, 2018 | -$1.30M | – |
| Q3 FY2018CQ1 2018 | Apr 30, 2018 | -$1.58M | – |
| Q2 FY2018CQ4 2017 | Jan 31, 2018 | -$2.02M | – |
| Q1 FY2018CQ3 2017 | Oct 31, 2017 | -$1.86M | – |
| Q4 FY2017CQ2 2017 | Jul 31, 2017 | -$1.34M | – |
| Q3 FY2017CQ1 2017 | Apr 30, 2017 | -$1.52M | – |
| Q2 FY2017CQ4 2016 | Jan 31, 2017 | -$1.34M | – |
| Q1 FY2017CQ3 2016 | Oct 31, 2016 | -$1.53M | – |
See a number that looks wrong?